Ekso Bionics Holdings Inc(EKSO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.39 | Insider Own | 24.25% | Shs Outstand | 3.6M | Perf Week | 3.78% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | 9.4% | Shs Float | 2.7M | Perf Month | 25.53% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 22.78% | Short Float | 7.97% | Perf Quarter | 25.93% |
| Income | -0.02B | P/S | 3.64 | EPS this Y | - | Inst Trans | -0.34% | Short Ratio | 2.21 | Perf Half Y | 131.37% |
| Sales | 0.01B | P/B | 20.12 | EPS next 5Y | - | ROA | -68.39% | Short Interest | 0.22M | Perf YTD | 36.57% |
| Book/sh | 0.59 | P/C | 10.54 | EPS past 3/5Y | 34.46% 31.73% | ROE | -217.36% | 52W High | -12.59% ($13.50) | Perf Year | 62.87% |
| Cash/sh | 1.12 | P/FCF | - | Sales past 3/5Y | -0.29% 7.58% | ROIC | -251.76% | 52W Low | 332.23% ($2.73) | Perf 3Y | -49.05% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 26.18% | Gross Margin | 52.86% | Volatility(W/M) | 7.55% 9.31% | Perf 5Y | -85.59% |
| Dividend TTM | - | EV/Sales | 3.98 | Sales Y/Y TTM | -34.08% | Oper. Margin | -134.06% | ATR (14) | 0.92 | Perf 10Y | -99.11% |
| Dividend Ex-Date | - | Quick Ratio | 1.03 | EPS Q/Q | -19.33% | Profit Margin | -138.91% | RSI (14) | 60.21 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.55 | Sales Q/Q | -36.56% | SMA20 | 11.72% ($10.56) | Beta | 0.86 | Target Price | $90 |
| Payout | - | Debt/Eq | 3.81 | Earnings | 2026/02/19 | SMA50 | 10.79% ($10.65) | Rel Volume | 0.99 | Prev Close | $11.79 |
| Employees | 55 | LT Debt/Eq | 2.05 | EPS/Sales Surpr. | 44.04% 1.7% | SMA200 | 72.7% ($6.83) | Avg Volume(3M) | 0.10M | Price | $11.8 |
| IPO | 2014/1/16 | Option/Short | No/Yes | Trades | 1116 | Volume | 96,572 | Change | 0.08% |
Company
EKSO is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US medical robotics company that builds wearable robotic exoskeletons to aid in the rehabilitation of stroke and spinal cord injury patients. Its flagship product is the EksoNR, and it is evolving into a smart rehabilitation robot equipped with NVIDIA AI voice control capabilities.
Over the past 1 year, on the higher side
13% below its 1-year high.
EKSO has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 1 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Would have changed by -49.0% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 22.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
DFAC 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $42M.
EKSO $42M PER -
ISRG $131B PER 42.4
BDX $48B PER 53.6
MDLN $43B PER 38.1
FAQ
What kind of company is EKSO?
EKSO belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of EKSO?
The market cap of EKSO is approximately $42M, ranking 5,010 within its sector.
What is the 52-week high and low for EKSO?
EKSO has recorded a 52-week high of $13.50 and a low of $2.73.
